login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ARCUS BIOSCIENCES INC (RCUS) Stock News
USA
-
New York Stock Exchange
- NYSE:RCUS -
US03969F1093
-
Common Stock
23.18
USD
+1.13 (+5.12%)
Last: 11/24/2025, 8:23:00 PM
21.63
USD
-1.55 (-6.69%)
Pre-Market:
11/25/2025, 4:32:08 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RCUS Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Arcus Biosciences
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
23 days ago - By: The Motley Fool
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
25 days ago - By: Arcus Biosciences
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
26 days ago - By: Arcus Biosciences
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
a month ago - By: Benzinga
Analyst Expectations For Arcus Biosciences's Future
a month ago - By: Arcus Biosciences
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
a month ago - By: Arcus Biosciences
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
a month ago - By: Benzinga
- Mentions:
GILD
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
a month ago - By: Stocktwits
- Mentions:
GILD
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
a month ago - By: Arcus Biosciences, Inc.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
2 months ago - By: Investor's Business Daily
- Mentions:
MRK
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
2 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
2 months ago - By: Arcus Biosciences
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
2 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
4 months ago - By: The Motley Fool
- Mentions:
GILD
Arcus (RCUS) Q2 Revenue Jumps 310%
3 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
3 months ago - By: Arcus Biosciences
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
3 months ago - By: Arcus Biosciences
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
4 months ago - By: Zacks Investment Research
- Mentions:
CHRS
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
4 months ago - By: Arcus Biosciences
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
4 months ago - By: Zacks Investment Research
- Mentions:
PCRX
Pacira (PCRX) Tops Q2 Earnings Estimates
4 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
5 months ago - By: Arcus Biosciences
Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
5 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
5 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
6 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
6 months ago - By: Arcus Biosciences
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
6 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
7 months ago - By: Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
7 months ago - By: Zacks Investment Research
- Mentions:
PCRX
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
7 months ago - By: Arcus Biosciences
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
Please enable JavaScript to continue using this application.